Why Is Neumora Therapeutics (NMRA) Stock Down -51% Today?
Key Takeaways
- NMRA shares are plunging approximately 51% in premarket trading on Monday, June 15, 2026, from a prior close of $1.78 to an indicated price near $0.87.
- Primary catalyst: Neumora's KOASTAL-2 and KOASTAL-3 Phase 3 trials of navacaprant in major depressive disorder (MDD) both failed to achieve statistically significant improvements on primary and key secondary endpoints versus placebo.
- Development discontinued: The company announced it is halting the entire navacaprant program for MDD following the double trial failure — the third Phase 3 miss for the drug.
- Workforce reduction: Neumora is cutting approximately 35% of its staff as it restructures around remaining pipeline assets, targeting roughly $10 million in annualized cost savings.
- Residual pipeline intact: The company will redirect resources toward NMRA-511 (Alzheimer's disease agitation), NMRA-898 (schizophrenia), and NMRA-215 (cardiometabolic disease).
- Traders are watching the company's cash runway, regulatory pathway for remaining pipeline candidates, and whether any strategic transaction — partnership or acquisition — emerges.
Opening Summary
Neumora Therapeutics (NMRA) is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, focused on developing treatments for neuropsychiatric and neurodegenerative diseases. Shares of NMRA are collapsing in premarket trading on June 15, 2026, down approximately 51% from Friday's closing price of $1.78, to an indicated level near $0.87. The devastating decline comes after the company disclosed before market open that its navacaprant antidepressant drug failed to meet primary and key secondary endpoints in both the KOASTAL-2 and KOASTAL-3 Phase 3 trials — and that it is permanently discontinuing the program.
Clinical Trial Failure: A Definitive Verdict on Navacaprant
The KOASTAL-2 and KOASTAL-3 results delivered a fatal blow to what had been Neumora's most important asset. Navacaprant, an oral kappa opioid receptor (KOR) antagonist, did not achieve statistically significant improvement in depressive symptoms compared to placebo, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS), the primary endpoint used in both trials. Key secondary endpoints also failed to reach significance, replicating the outcome of the KOASTAL-1 trial that had already crashed NMRA shares by more than 80% in early January 2025.
The magnitude of today's sell-off reflects the complete elimination of the program's residual option value. After KOASTAL-1 failed, the market assigned non-trivial probability to a recovery in the successor studies — particularly after Neumora restructured KOASTAL-2 and KOASTAL-3 to improve site selection, tighten enrollment criteria, and add independent medical monitoring from Massachusetts General Hospital. That thesis has now been decisively rejected. The company stated that the safety profile remained consistent with prior studies, meaning there were no new safety signals, but that is cold comfort when efficacy has failed across all three pivotal trials.
Restructuring and Workforce Reduction
Alongside the clinical data announcement, Neumora disclosed a broad operational restructuring. The company is eliminating approximately 35% of its workforce, a move targeting roughly $10 million in annualized cost savings. The restructuring signals a hard pivot away from navacaprant and toward the company's earlier-stage pipeline, which includes NMRA-511 for Alzheimer's disease-related agitation — which showed clinically meaningful Phase 1b results earlier in 2026 — NMRA-898 and NMRA-861, M4 muscarinic receptor positive allosteric modulators targeting schizophrenia, and NMRA-215, a brain-penetrant NLRP3 inhibitor in Phase 1 for obesity and cardiometabolic conditions. While the retained pipeline represents real scientific optionality, none of these programs is near commercial readiness, and the elimination of navacaprant removes the only asset that had reached Phase 3.
Market Context and Trading Activity
The premarket sell-off in NMRA is company-specific and driven almost entirely by the clinical data disclosure rather than any broader sector or macro move. Biotech ETFs including XBI and IBB are not showing sympathy weakness of comparable magnitude, confirming this is an idiosyncratic event. Trading volume in NMRA premarket is running at multiples of its average daily volume of approximately 676,000 shares — consistent with the pattern seen during the KOASTAL-1 failure in January 2025, when volume surged dramatically. Technically, the stock has been trading near multi-year lows since early 2025, having already lost the vast majority of its market capitalization following the first navacaprant failure. Today's move pushes shares to new all-time lows, eliminating prior technical support levels entirely and placing the stock in uncharted territory at sub-$1 levels.
Trending AI Robots
Navigating volatile biotech moves like the dramatic decline in NMRA requires timely data and disciplined execution. Tickeron's Trending AI Robots page curates the strongest-performing AI trading bots from Tickeron's broader library of hundreds of bots covering thousands of tickers. Not all bots make the cut — only those demonstrating top-tier performance under current market conditions are featured. Each bot differs in strategy type, holding timeframe, traded symbols, and risk parameters, giving traders a range of approaches from short-term momentum plays to longer swing-trading setups. Investors and active traders looking to add a systematic, data-driven layer to their decision-making process may find Tickeron's AI tools worth exploring.
What Comes Next for NMRA
With navacaprant fully discontinued, all of Neumora's near-term clinical narrative hinges on its remaining pipeline. NMRA-511's Phase 1b data in Alzheimer's disease agitation drew positive attention earlier in 2026, and a Phase 2 decision is the next likely catalyst to watch. The M4 PAM franchise — NMRA-898 and NMRA-861 — is in Phase 1, with a comprehensive update expected in mid-2026. The company's cash position and how far into 2027 it can sustain operations will be a central focus for investors assessing whether NMRA has sufficient runway to generate value-creating data readouts. There is also speculation in biotech circles about whether a company trading near or below cash value could become a restructuring or acquisition target, though no formal process has been announced. Regulatory and clinical execution risk remains elevated across all remaining programs.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
NMRA's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for NMRA turned positive on June 23, 2026. Looking at past instances where NMRA's MACD turned positive, the stock continued to rise in of 16 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NMRA's RSI Indicator exited the oversold zone, of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 30, 2026. You may want to consider a long position or call options on NMRA as a result. In of 42 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where NMRA advanced for three days, in of 155 cases, the price rose further within the following month. The odds of a continued upward trend are .
NMRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 30 cases where NMRA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NMRA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for NMRA entered a downward trend on June 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.195) is normal, around the industry mean (21.001). P/E Ratio (0.000) is within average values for comparable stocks, (36.006). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). NMRA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.000) is also within normal values, averaging (368.009).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NMRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NMRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement